166 related articles for article (PubMed ID: 35697070)
1. Structural and mechanistic insights into the inhibition of type I-F CRISPR-Cas system by anti-CRISPR protein AcrIF23.
Ren J; Wang H; Yang L; Li F; Wu Y; Luo Z; Chen Z; Zhang Y; Feng Y
J Biol Chem; 2022 Jul; 298(7):102124. PubMed ID: 35697070
[TBL] [Abstract][Full Text] [Related]
2. Anti-CRISPR protein AcrIF4 inhibits the type I-F CRISPR-Cas surveillance complex by blocking nuclease recruitment and DNA cleavage.
Gao Z; Zhang L; Ge Z; Wang H; Yue Y; Jiang Z; Wang X; Xu C; Zhang Y; Yang M; Feng Y
J Biol Chem; 2022 Nov; 298(11):102575. PubMed ID: 36209819
[TBL] [Abstract][Full Text] [Related]
3. AcrIF5 specifically targets DNA-bound CRISPR-Cas surveillance complex for inhibition.
Xie Y; Zhang L; Gao Z; Yin P; Wang H; Li H; Chen Z; Zhang Y; Yang M; Feng Y
Nat Chem Biol; 2022 Jun; 18(6):670-677. PubMed ID: 35301482
[TBL] [Abstract][Full Text] [Related]
4. Mechanistic insights into the inhibition of the CRISPR-Cas surveillance complex by anti-CRISPR protein AcrIF13.
Wang H; Gao T; Zhou Y; Ren J; Guo J; Zeng J; Xiao Y; Zhang Y; Feng Y
J Biol Chem; 2022 Mar; 298(3):101636. PubMed ID: 35085557
[TBL] [Abstract][Full Text] [Related]
5. A Type I-F Anti-CRISPR Protein Inhibits the CRISPR-Cas Surveillance Complex by ADP-Ribosylation.
Niu Y; Yang L; Gao T; Dong C; Zhang B; Yin P; Hopp AK; Li D; Gan R; Wang H; Liu X; Cao X; Xie Y; Meng X; Deng H; Zhang X; Ren J; Hottiger MO; Chen Z; Zhang Y; Liu X; Feng Y
Mol Cell; 2020 Nov; 80(3):512-524.e5. PubMed ID: 33049228
[TBL] [Abstract][Full Text] [Related]
6. Structural basis of AcrIF24 as an anti-CRISPR protein and transcriptional suppressor.
Mukherjee IA; Gabel C; Noinaj N; Bondy-Denomy J; Chang L
Nat Chem Biol; 2022 Dec; 18(12):1417-1424. PubMed ID: 36163386
[TBL] [Abstract][Full Text] [Related]
7. How type II CRISPR-Cas establish immunity through Cas1-Cas2-mediated spacer integration.
Xiao Y; Ng S; Nam KH; Ke A
Nature; 2017 Oct; 550(7674):137-141. PubMed ID: 28869593
[TBL] [Abstract][Full Text] [Related]
8. Multiple mechanisms for CRISPR-Cas inhibition by anti-CRISPR proteins.
Bondy-Denomy J; Garcia B; Strum S; Du M; Rollins MF; Hidalgo-Reyes Y; Wiedenheft B; Maxwell KL; Davidson AR
Nature; 2015 Oct; 526(7571):136-9. PubMed ID: 26416740
[TBL] [Abstract][Full Text] [Related]
9. Mechanistic insights into DNA binding and cleavage by a compact type I-F CRISPR-Cas system in bacteriophage.
Zhang M; Peng R; Peng Q; Liu S; Li Z; Zhang Y; Song H; Yang J; Xing X; Wang P; Qi J; Gao GF
Proc Natl Acad Sci U S A; 2023 May; 120(18):e2215098120. PubMed ID: 37094126
[TBL] [Abstract][Full Text] [Related]
10. Structure Reveals a Mechanism of CRISPR-RNA-Guided Nuclease Recruitment and Anti-CRISPR Viral Mimicry.
Rollins MF; Chowdhury S; Carter J; Golden SM; Miettinen HM; Santiago-Frangos A; Faith D; Lawrence CM; Lander GC; Wiedenheft B
Mol Cell; 2019 Apr; 74(1):132-142.e5. PubMed ID: 30872121
[TBL] [Abstract][Full Text] [Related]
11. Insights into the inhibition of type I-F CRISPR-Cas system by a multifunctional anti-CRISPR protein AcrIF24.
Yang L; Zhang L; Yin P; Ding H; Xiao Y; Zeng J; Wang W; Zhou H; Wang Q; Zhang Y; Chen Z; Yang M; Feng Y
Nat Commun; 2022 Apr; 13(1):1931. PubMed ID: 35411005
[TBL] [Abstract][Full Text] [Related]
12. Cas1 and Cas2 From the Type II-C CRISPR-Cas System of
He Y; Wang M; Liu M; Huang L; Liu C; Zhang X; Yi H; Cheng A; Zhu D; Yang Q; Wu Y; Zhao X; Chen S; Jia R; Zhang S; Liu Y; Yu Y; Zhang L
Front Cell Infect Microbiol; 2018; 8():195. PubMed ID: 29951376
[TBL] [Abstract][Full Text] [Related]
13. Cas1-Cas2 complex formation mediates spacer acquisition during CRISPR-Cas adaptive immunity.
Nuñez JK; Kranzusch PJ; Noeske J; Wright AV; Davies CW; Doudna JA
Nat Struct Mol Biol; 2014 Jun; 21(6):528-34. PubMed ID: 24793649
[TBL] [Abstract][Full Text] [Related]
14. Disabling a Type I-E CRISPR-Cas Nuclease with a Bacteriophage-Encoded Anti-CRISPR Protein.
Pawluk A; Shah M; Mejdani M; Calmettes C; Moraes TF; Davidson AR; Maxwell KL
mBio; 2017 Dec; 8(6):. PubMed ID: 29233895
[TBL] [Abstract][Full Text] [Related]
15. A phage-encoded anti-CRISPR enables complete evasion of type VI-A CRISPR-Cas immunity.
Meeske AJ; Jia N; Cassel AK; Kozlova A; Liao J; Wiedmann M; Patel DJ; Marraffini LA
Science; 2020 Jul; 369(6499):54-59. PubMed ID: 32467331
[TBL] [Abstract][Full Text] [Related]
16. Structural and mechanistic insights into the CRISPR inhibition of AcrIF7.
Kim I; Koo J; An SY; Hong S; Ka D; Kim EH; Bae E; Suh JY
Nucleic Acids Res; 2020 Sep; 48(17):9959-9968. PubMed ID: 32810226
[TBL] [Abstract][Full Text] [Related]
17. Anti-CRISPR AcrIE2 Binds the Type I-E CRISPR-Cas Complex But Does Not Block DNA Binding.
Mejdani M; Pawluk A; Maxwell KL; Davidson AR
J Mol Biol; 2021 Feb; 433(3):166759. PubMed ID: 33338493
[TBL] [Abstract][Full Text] [Related]
18. Distinct Subcellular Localization of a Type I CRISPR Complex and the Cas3 Nuclease in Bacteria.
Govindarajan S; Borges A; Karambelkar S; Bondy-Denomy J
J Bacteriol; 2022 May; 204(5):e0010522. PubMed ID: 35389256
[TBL] [Abstract][Full Text] [Related]
19. Structural plasticity and in vivo activity of Cas1 from the type I-F CRISPR-Cas system.
Wilkinson ME; Nakatani Y; Staals RH; Kieper SN; Opel-Reading HK; McKenzie RE; Fineran PC; Krause KL
Biochem J; 2016 Apr; 473(8):1063-72. PubMed ID: 26929403
[TBL] [Abstract][Full Text] [Related]
20. Foreign DNA acquisition by the I-F CRISPR-Cas system requires all components of the interference machinery.
Vorontsova D; Datsenko KA; Medvedeva S; Bondy-Denomy J; Savitskaya EE; Pougach K; Logacheva M; Wiedenheft B; Davidson AR; Severinov K; Semenova E
Nucleic Acids Res; 2015 Dec; 43(22):10848-60. PubMed ID: 26586803
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
